Fumarate hydratase as a therapeutic target in renal cancer

References

• Low G, Huang G, Fu W, et al. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 2016;8(5):484–500.
   PubMed Web of Science ®Google Scholar
• Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015;48(3):166–174.
   PubMedGoogle Scholar
• Diaz de Leon A, Pedrosa I. Imaging and screening of kidney cancer. Radiol Clin North Am. 2017;55(6):1235–1250.
   PubMed Web of Science ®Google Scholar
• Caoili EM, Davenport MS. Role of percutaneous needle biopsy for renal masses. Semin Intervent Radiol. 2014;31(1):20–26.
   PubMed Web of Science ®Google Scholar
• Lopes Vendrami C, Parada Villavicencio C, DeJulio TJ, et al. Differentiation of solid renal tumors with multiparametric MR imaging. Radiographics. 2017;37(7):2026–2042.
   PubMed Web of Science ®Google Scholar
• Ghoneim IA, Fergany AF. Minimally invasive surgery for renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9(7):989–997.
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol. 2016;70(1):106–119.
   PubMed Web of Science ®Google Scholar
• Udager AM, Mehra R. Morphologic, molecular, and taxonomic evolution of renal cell carcinoma: a conceptual perspective with emphasis on updates to the 2016 world health organization classification. Arch Pathol Lab Med. 2016;140(10):1026–1037.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Carrasco JC, Cheng L, et al. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol. 2009;16(5):432–443.
   PubMed Web of Science ®Google Scholar
• Kara O, Maurice MJ, Zargar H, et al. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. Int Urol Nephrol. 2016;48(8):1253–1260.
   PubMed Web of Science ®Google Scholar
• Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am. 2008;35(4):581–92; vi.
   PubMed Web of Science ®Google Scholar
• Montironi R, Cheng L, Scarpelli M, et al. Pathology and genetics: tumours of the urinary system and male genital system: clinical implications of the 4th edition of the who classification and beyond. Eur Urol. 2016;70(1):120–123.
   PubMed Web of Science ®Google Scholar
• Tsuda K, Kinouchi T, Tanikawa G, et al. Imaging characteristics of papillary renal cell carcinoma by computed tomography scan and magnetic resonance imaging. Int J Urol. 2005;12(9):795–800.
   PubMed Web of Science ®Google Scholar
• Magers MJ, Perrino CM, Cramer HM, et al. Cytomorphologic comparison of type 1 and type 2 papillary renal cell carcinoma: A retrospective analysis of 28 cases. Cancer Cytopathol; 2019. 127:370–6
   PubMed Web of Science ®Google Scholar
• Liu K, Ren Y, Pang L, et al. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study. Int J Clin Exp Pathol. 2015;8(7):8311–8335.
   PubMed Web of Science ®Google Scholar
• Skala SL, Dhanasekaran SM, Mehra R. Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC): a contemporary review and practical discussion of the differential diagnosis for HLRCC-associated renal cell carcinoma. Arch Pathol Lab Med. 2018;142(10):1202–1215.
   PubMed Web of Science ®Google Scholar
• Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol. 2010;34(11):1608–1621.
   PubMed Web of Science ®Google Scholar
• Merino MJ, Torres-Cabala C, Pinto P, et al., The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31(10):1578–1585.
   PubMed Web of Science ®Google Scholar
• Bardella C, El-Bahrawy M, Frizzell N, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol. 2011;225(1):4–11.
   PubMed Web of Science ®Google Scholar
• Launonen V, Vierimaa O, Kiuru M, et al., Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98(6):3387–3392.
   PubMed Web of Science ®Google Scholar
• Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406–410.
   PubMed Web of Science ®Google Scholar
• Gellera C, Uziel G, Rimoldi M, et al. Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology. 1990;40(3 Pt 1):495–499.
   PubMed Web of Science ®Google Scholar
• Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis. 2014;7:253–260.
   PubMedGoogle Scholar
• Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38(5):627–637.
   PubMed Web of Science ®Google Scholar
• Grubb RL 3rd, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177(6):2074–2079. discussion 2079-80.
   PubMed Web of Science ®Google Scholar
• Bulku A, Weaver TM, Berkmen MB. Biochemical characterization of two clinically-relevant human fumarase variants defective for oligomerization. Open Biochem J. 2018;12:1–15.
   PubMedGoogle Scholar
• Rose IA, Weaver TM. The role of the allosteric B site in the fumarase reaction. Proc Natl Acad Sci U S A. 2004;101(10):3393–3397.
   PubMed Web of Science ®Google Scholar
• Alam NA, Olpin S, Rowan A, et al. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn. 2005;7(4):437–443.
   PubMed Web of Science ®Google Scholar
• Picaud S, Kavanagh KL, Yue WW, et al. Structural basis of fumarate hydratase deficiency. J Inherit Metab Dis. 2011;34(3):671–676.
   PubMed Web of Science ®Google Scholar
• Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43(1):18–27.
   PubMed Web of Science ®Google Scholar
• Lorenzato A, Olivero M, Perro M, et al. A cancer-predisposing “hot spot” mutation of the fumarase gene creates a dominant negative protein. Int J Cancer. 2008;122(4):947–951.
   PubMed Web of Science ®Google Scholar
• Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet. 2008;9:20.
   PubMed Web of Science ®Google Scholar
• King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675–4682.
   PubMed Web of Science ®Google Scholar
• Sudarshan S, Sourbier C, Kong H-S, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol. 2009;29(15):4080–4090.
   PubMed Web of Science ®Google Scholar
• Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer–targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19(13):3345–3352.
   PubMed Web of Science ®Google Scholar
• Yang Y, Valera VA, Padilla-Nash HM, et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet. 2010;196(1):45–55.
   PubMedGoogle Scholar
• Bratslavsky G, Sudarshan S, Neckers L, et al., Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res. 2007;13(16):4667–4671.
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian Y-M, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang G-W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.
   PubMed Web of Science ®Google Scholar
• Pollard PJ, Wortham NC, Tomlinson IP. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med. 2003;35(8):632–639.
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8(2):143–153.
   PubMed Web of Science ®Google Scholar
• O’Flaherty L, Adam J, Heather LC, et al. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum Mol Genet. 2010;19(19):3844–3851.
   PubMed Web of Science ®Google Scholar
• Yang Y, Valera V, Sourbier C, et al. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet. 2012;205(7–8):377–390.
   PubMed Web of Science ®Google Scholar
• Zheng L, Cardaci S, Jerby L, et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat Commun. 2015;6:6001.
   PubMed Web of Science ®Google Scholar
• Sullivan LB, Martinez-Garcia E, Nguyen H, et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell. 2013;51(2):236–248.
   PubMed Web of Science ®Google Scholar
• Ooi A, Wong J-C, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20(4):511–523.
   PubMed Web of Science ®Google Scholar
• Adam J, Hatipoglu E, O’Flaherty L, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20(4):524–537.
   PubMed Web of Science ®Google Scholar
• Yang Y, Lane AN, Ricketts CJ, et al. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One. 2013;8(8):e72179.
   PubMed Web of Science ®Google Scholar
• Laukka T, Mariani CJ, Ihantola T, et al. Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. J Biol Chem. 2016;291(8):4256–4265.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Valle VD, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289–2301.
   PubMed Web of Science ®Google Scholar
• Sciacovelli M, Gonçalves E, Johnson TI, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016;537(7621):544–547.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
   PubMed Web of Science ®Google Scholar
• Yogev O, Yogev O, Singer E, et al. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol. 2010;8(3):e1000328.
   PubMed Web of Science ®Google Scholar
• Lehtonen HJ, Mäkinen MJ, Kiuru M, et al. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. Int J Cancer. 2007;121(6):1386–1389.
   PubMed Web of Science ®Google Scholar
• Dik E, Naamati A, Asraf H, et al. Human fumarate hydratase is dual localized by an alternative transcription initiation mechanism. Traffic. 2016;17(7):720–732.
   PubMed Web of Science ®Google Scholar
• Sass E, Karniely S, Pines O. Folding of fumarase during mitochondrial import determines its dual targeting in yeast. J Biol Chem. 2003;278(46):45109–45116.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Qian X, Shen J, et al. Author Correction: local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol. 2018;20(10):1226.
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Sundaram RK, Oeck S, et al. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet. 2018;50(8):1086–1092.
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Gurram S, Al Harthy M, et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J Clin Oncol. (2020 ASCO Virtual Scientific Program). 2020;38:5004.
   PubMed Web of Science ®Google Scholar
• Choi Y, Keam B, Kim M, et al. Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients. Cancer Res Treat. 2019;51(4):1549–1556.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Kidney Cancer. [ cited 2019 August 5]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
   Google Scholar
• Schaefer IM, Hornick JL, Bovee J. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Lab Invest. 2018;98(4):414–426.
   PubMed Web of Science ®Google Scholar
• Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017;355(6330):1147–1152.
   PubMed Web of Science ®Google Scholar
• Linnekamp JF, Butter R, Spijker R, et al. Clinical and biological effects of demethylating agents on solid tumours - A systematic review. Cancer Treat Rev. 2017;54:10–23.
   PubMed Web of Science ®Google Scholar
• Xie H, Valera VA, Merino MJ, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther. 2009;8(3):626–635.
   PubMed Web of Science ®Google Scholar
• Woodford MR, Chen VZ, Backe SJ, et al., Structural and functional regulation of lactate dehydrogenase-A in cancer. Future Med Chem. 2020;12(5):439–455.
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Tran TAT, Oz OK, et al. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol. 2011;8(3):165–171.
   PubMed Web of Science ®Google Scholar
• Sourbier C, Valera-Romero V, Giubellino A, et al. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle. 2010;9(20):4183–4189.
   PubMed Web of Science ®Google Scholar
• Sourbier C, Ricketts CJ, Liao PJ, et al. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. Sci Rep. 2019;9(1):18409.
   PubMedGoogle Scholar
• Perrier-Trudova V, Huimin BW, Kongpetch S, et al. Fumarate hydratase-deficient cell line NCCFH1 as a new in vitro model of hereditary papillary renal cell carcinoma type 2. Anticancer Res. 2015;35(12):6639–6653.
   PubMed Web of Science ®Google Scholar
• Sourbier C, Ricketts C, Matsumoto S, et al. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. Cancer Cell. 2014;26(6):840–850.
   PubMed Web of Science ®Google Scholar
• Greuber EK, Smith-Pearson P, Wang J, et al. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13(8):559–571.
   PubMed Web of Science ®Google Scholar
• Dunn DM, Woodford M, Truman A, et al. c-Abl mediated tyrosine phosphorylation of Aha1 activates its co-chaperone function in cancer cells. Cell Rep. 2015;12(6):1006–1018.
   PubMed Web of Science ®Google Scholar
• Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell. 2011;20(3):315–327.
   PubMed Web of Science ®Google Scholar
• Frezza C, Zheng L, Folger O, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477(7363):225–228.
   PubMed Web of Science ®Google Scholar
• Vanharanta S, Pollard PJ, Lehtonen HJ, et al. Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet. 2006;15(1):97–103.
   PubMed Web of Science ®Google Scholar
• Podkalicka P, Mucha O, Kruczek S, et al. Synthetically lethal interactions of heme oxygenase-1 and fumarate hydratase genes. Biomolecules. 2020;10(1):143.
   Web of Science ®Google Scholar
• Zheng L, MacKenzie ED, Karim SA, et al. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab. 2013;1(1):12.
   PubMedGoogle Scholar
• Boettcher M, Lawson A, Ladenburger V, et al. High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. BMC Genomics. 2014;15:158.
   PubMed Web of Science ®Google Scholar
• Costa B, Dettori D, Lorenzato A, et al. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. Faseb J. 2010;24(8):2680–2688.
   PubMed Web of Science ®Google Scholar
• Koski TA, Lehtonen HJ, Jee KJ, et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer. 2009;48(7):544–551.
   PubMed Web of Science ®Google Scholar
• Prisciandaro M, Ratta R, Massari F, et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program. Am J Clin Oncol. 2019;42(1):42–45.
   PubMed Web of Science ®Google Scholar
• Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018;104:188–194.
   PubMed Web of Science ®Google Scholar
• Alaghehbandan R, Stehlik J, Trpkov K, et al. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol. 2017;29:17–22.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–1385.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015;21(5):1071–1077.
   PubMed Web of Science ®Google Scholar